echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Mercadon's second-quarter results: Total revenue of $10.9 billion K drug sold for $3.4 billion!

    Mercadon's second-quarter results: Total revenue of $10.9 billion K drug sold for $3.4 billion!

    • Last Update: 2020-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Read: Mercadon recently reported second-quarter 2020 results: Global sales of $10.9 billion, down 8% year-on-year.
    , motheton, recently reported second-quarter 2020 results of $10.9 billion, down 8% year-on-year, excluding foreign exchange, global sales fell 5%.
    pharmaceutical business revenue of $9.7 billion, down 7% year-on-year, while sales fell 6 percent, excluding foreign exchange adverse effects. The decline in the pharmaceutical business
    was mainly due to the negative impact of the outbreak on vaccines and hospital emergency care products, as well as the continuing impact of the loss of market ownership of some products, which was partially offset by strong growth in the oncology business. Keytruda's sales rose 29 percent to $3.4 billion in the
    oncology business, driven by the continued strength of non-small cell lung cancer adaptation and the continued absorption of other indications, including assisted treatments for melanoma, kidney cell carcinoma, bladder cancer, head and neck cancer, and hypercomputerinstability (MSI-H) cancers.
    high co-op revenues associated with Lynparza and Lenvima also contributed to the growth of the oncology business, reflecting continued market penetration of approved indications in the U.S., Europe and China.
    Mersadon has narrowed its full-year 2020 revenue range to $47.2-48.7 billion, of which the negative impact on foreign exchange is approximately 2%, and the gaAPEPS range for the full year 2020 has been narrowed to $4.58-4.73, and the non-GAAPEPS range has been narrowed and increased to $5.63-5.78, of which the negative impact on foreign exchange is about 3 percent.
    the following pipeline highlights for The following: (1) COVID-19 related research highlights: - V590: Working with IAVI to develop a COVID-19 vaccine based on a recombinant blister oral inflammatory virus (rVSV) platform that uses the same platform as the approved Ebola virus vaccine in Mershadon.
    currently, V590 is in preclinical development and is expected to launch a clinical research project this year.
    - V591: Acquired Themis to accelerate the development of a COVID-19 vaccine based on a measles virus vector platform, originally developed by scientists at the Pasteur Institute, with theirs obtaining exclusive licenses.
    currently in preclinical development, V591 is expected to launch a clinical research project in the third quarter.
    - MK-4482: An oral antiviral drug developed in collaboration with RidgebackBio for the treatment of COVID-19.
    in preclinical studies, the drug showed antiviral activity against a variety of viruses, including SARS-CoV-2, as well as coronaviruses that cause MERS and SARS.
    at present, the drug is in Phase II clinical.
    - Other: Mercado is working with the American Institute of Systems Biology (ISB) to study and identify the molecular mechanisms of SARS-CoV-2 infection and COVID-19 infection, identify drugs and vaccine targets, and join the Accelerated COVID-19 Therapeutic Intervention and Vaccine Alliance led by the National Institutes of Health (NIH).
    (2) Tumor Pipeline Highlights: - Keytruda: Achieved several regulatory milestones, including four approvals from the U.S. FDA, one approval from NMPA in China, and three sBlas accepted by the FDA (2 priority reviews, 1 standard review).
    Lynparza: PARP inhibitors developed in partnership with AstraZeneca have also achieved a number of regulatory milestones, including two approvals from the U.S. FDA and one approval from the European Union EC.
    - Lenvima: Multikinase inhibitors developed in collaboration with Aishi, have made several clinical advances: the keytruda-Lenvima program is a front-line treatment of hepatocellular carcinoma (HCC) and the treatment of immunocheckpoint inhibitorrefractable transparent cell nephricular cell cell cell cancer has been highly efficacy data.
    regulatory aspect, the program's first-line treatment hCC's sBLA received a full FDA response because the Roche Tecentriq-Avastin portfolio has been approved for first-line treatment of HCC and has total lifetime benefits, and the available evidence does not support the keytruda-Lenvima solution to have a meaningful advantage over the Roche portfolio.
    ——MK-6482:-2α(HIF-2α),II,·(VHL)(ccRCC),27.9%、。
    just recently, the drug was approved by the FDA for breakthrough drug.
    (3) Vaccine Pipeline Highlights:-V114: In the study of 15 pneumococcal conjugate vaccine, 2 adult Phase III studies PNEU-WAY (V114-018) and PNEU-FLU (V114-021) were successful, reaching safety and immunogenicity goals.
    - GARDASIL9: Recombinant HPV 9-valent vaccine approved by the U.S. FDA to prevent oral and other throat cancers and other head and neck cancers caused by seven high-risk types of HPV (16, 18, 31, 33, 45, 52, 58).
    (4) Other Pipeline Highlights: -vericiguat: The first oral sGC stimulant developed in collaboration with Bayer, a new drug application that was reviewed by the FDA as a priority, combined with other heart failure drugs used in patients with chronic heart failure with reduced blood score, and reduced the risk of cardiovascular death and cardiac failure hospitalization after a worsening heart failure event.
    - islatravir: New analytical data were published in the IIb phase study of oral nucleoside reverse transcriptase translocation inhibitors, joint doravirine first-line treatment of HIV-1 adults.
    48-week data strengthens the efficacy and safety of combination drug use as a first-line treatment of HIV-1 infection as a second drug.
    - Recarbrio: A new compound antibiotic product approved by the U.S. FDA for a new indication for hospital-acquired bacterial pneumonia and ventilator-related bacterial pneumonia in adults 18 years and older.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.